Skip Navigation



NDT Advance Access published online on April 9, 2007

Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfm148
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/7/2038    most recent
gfm148v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schmitt, C. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmitt, C. P.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Reduced systemic advanced glycation endproducts in children receiving peritoneal dialysis with low glucose degradation product content

Claus Peter Schmitt1, Dorothee von Heyl1, Susanne Rieger1, Klaus Arbeiter2, Klaus Eugen Bonzel3, Michel Fischbach4, Joachim Misselwitz5, Ann-Kathrin Pieper6 and Franz Schaefer1 for the Mid European Pediatric Peritoneal Dialysis Study Group (MEPPS)

1University Hospital for Pediatric & Adolescent Medicine, University of Heidelberg, Germany, 2Children's Hospital, University of Vienna, Austria, 3Children's Hospital, University of Essen, Germany, 4Hopital de Hautepierre, University of Strasbourg, France, 5Children's Hospital, University of Jena and 6Charité Children's Hospital, Humboldt University, Berlin, Germany

Correspondence and offprint requests to: Claus Peter Schmitt, MD, Division of Pediatric Nephrology, University Hospital for Pediatric and Adolescent Medicine, Im Neuenheimer Feld 153, 69120 Heidelberg, Germany. Email: claus.peter.schmitt{at}med.uni-heidelberg.de



  Abstract

Background. Glucose degradation products (GDP) in peritoneal dialysis (PD) solutions are toxic to the peritoneal membrane and promote the formation of advanced glycation end products (AGE), which contribute to accelerated atherosclerosis and amyloidosis. Double chamber PD solutions have a markedly reduced GDP content.

Methods. We analysed GDP and AGE kinetics in 21 children (7 months to 18 years) on automated PD in a prospective multicentre trial with randomized administration of single chamber, high-GDP and double-chamber, low-GDP dialysis solution for 12 weeks each. Total AGE fluorescence, carboxymethyllysine (CML, ELISA) and 3-deoxyglucosone (3-DG, HPLC) were measured in plasma and PD effluent during a 4 h peritoneal equilibration test. Plasma AGE profiles were assessed by size selective gel permeation chromatography and compared with 23 healthy controls.

Results. Initial effluent 3-DG concentrations were 140 ± 55 and 25 ± 4 µmol/l with high- and low-GDP PD fluid, respectively and declined to 53 ± 32 and 7 ± 2 µmol/l within 4 h dwell time (P < 0.001). The ex vivo AGE generating capacity was three times higher with the high-GDP solution and decreased significantly with dwell time. Plasma AGE levels were 1.8–7.4-fold above those of healthy controls; the elevation was most marked for the small molecular fraction (<2 kDa). Plasma AGE and CML levels were significantly higher after 12 weeks exposure to high-GDP solution (20991 ± 4145 AU and 1505 ± 617 ng/ml) than following treatment with low-GDP fluid (17518 ± 4676 AU and 1151 ± 438 ng/ml; both P < 0.05). Four hour AGE clearance was higher with low-GDP solution (0.74 ± 0.3 vs 0.44 ± 0.15 ml/min*1.73 m2, P < 0.01).

Conclusion. GDP are rapidly absorbed from the peritoneal cavity. Administration of PD solutions with low-GDP content reduces plasma AGE levels and may thus improve the cardiovascular risk profile of dialysed children.

Keywords: advanced glycation endproducts; biocompatibility; children; glucose degradation products; peritoneal dialysis

Received for publication: 12. 1.07
Accepted in revised form: 26. 2.07


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
pdiHome page
L. Weiss, B. Stegmayr, G. Malmsten, M. Tejde, H. Hadimeri, C. E. Siegert, J. Ahlmen, R. Larsson, B. Ingman, O. Simonsen, et al.
BIOCOMPATIBILITY AND TOLERABILITY OF A PURELY BICARBONATE-BUFFERED PERITONEAL DIALYSIS SOLUTION
Perit. Dial. Int., November 1, 2009; 29(6): 647 - 655.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
S. Kim, J. Oh, S. Kim, W. Chung, C. Ahn, S. G. Kim, and K.-H. Oh
Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study
Nephrol. Dial. Transplant., September 1, 2009; 24(9): 2899 - 2908.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.